Esperion's cholesterol-lowering drug clears test in diabetics

A phase 2 of Esperion’s bempedoic acid-ezetimibe combination in Type 2 diabetics with high cholesterol has met its primary endpoint. The trial provides evidence the combination can lower cholesterol without negatively affecting blood sugar levels.